Barbara Fox is the new CEO of Rheos Medicines. She was most recently chief executive of Tilos Therapeutics, which was acquired by Merck (NYSE: [[ticker:MRK]]) earlier this year. Fox succeeds interim Rheos CEO Abbie Celniker, a partner at Third Rock Ventures. Celniker will remain chair of the Rheos board of directors. Cambridge, MA-based Rheos emerged last year with $60 million in Series A financing to develop drugs that target cellular metabolism as a way to treat disease.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
